Skip to main content

Table 1 Clinical and demographic characteristics at enrollment (N = 52)

From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Characteristic All patients First-line treatment Second-line treatment
  Number (%) Number (%) Number (%)
   30 (57.7) 22 (42.3)
Median age (range), years 60 (32-70) 60 (32-70) 60 (26-68)
ECOG score
0 20 (38.5) 10 (33.3) 10 (45.5)
1 32 (61.5) 20 (67.7) 12 (54.5)
Sex
Male 32 (61.5) 18 (60.0) 14 (63.6)
Female 20 (38.5) 12 (40.0) 8 (36.4)
Primary lesion site
Colon 32 (61.5) 16 (53.3) 16 (72.7)
Rectum 20 (38.5) 14 (46.7) 6 (27.3)
Positive history of diabetes 9 (17.3) 5 (16.7) 4 (18.2)
Primary tumor resection 46 (88.5) 26 (86.7) 20 (90.9)
Site of metastasis
Liver 31 (59.6) 16 (53.3) 15 (68.2)
Lung 18 (34.6) 13 (43.3) 5 (22.7)
Abdominal cavity 18 (34.6) 8 (26.7) 10 (45.5)
Number of metastatic lesions
Single 24 (46.2) 15 (50.0) 9 (40.9)
Multiple 28 (53.8) 15 (50.0) 13 (59.1)
  1. ECOG: Eastern Cooperative Oncology Group.